Literature DB >> 21116732

Long-term results of biliopancreatic diversion with or without gastric preservation for morbid obesity.

Nicola Crea1, Giacomo Pata, Ernesto Di Betta, Francesco Greco, Claudio Casella, Antonio Vilardi, Francesco Mittempergher.   

Abstract

We aimed at comparing our long-term results after biliopancreatic diversion (BPD) with or without gastric preservation for morbid obesity. Between 1999 and 2009, we performed 540 BPD: 287 patients (group A) underwent BPD with distal gastric resection (BPD-AHS) and 253 (group B) underwent BPD associated with transitory vertical gastroplasty (TGR) with duodenal switch (DS). The results have been analyzed in terms of weight loss, improvement of comorbidities, and quality of life (Bariatric Analysis and Reporting Outcome System). The mean follow-up was 7.4 ± 2.9 years. One year after surgery, mean initial excess weight loss percentage was 69% for patients in group A (n = 287) and 65% for group B (n = 253); after 2-5 years, it was 74% for patients who underwent BPD-AHS (n = 130) and 75% for patients who underwent BPD-TGR-DS (n = 116); it was 71% and 74% for patients in group A (n = 157) and B (n = 137), respectively, followed up for >5 years (P = 0.27). Among the diabetic patients in both groups (191 patients), 64% discontinued the medication with insulin (P = 0.25), and 98% had stopped oral drugs within 1 year from surgery (P = 0.29). We did not observe deficiencies of vitamins and proteins. The overall incidence of incisional hernias was 38% (P = 0.35). We recorded 13 anastomotic ulcers (2.4%; P = 0.28). BPD represents, in spite of the side effects, an effective technique for treatment of morbid obesity and its associated diseases. Moreover, our results showed that patients who underwent BPD-TGR-DS had slightly better results in terms of postoperative metabolic complications and improvement in quality of life.

Entities:  

Mesh:

Year:  2011        PMID: 21116732     DOI: 10.1007/s11695-010-0333-6

Source DB:  PubMed          Journal:  Obes Surg        ISSN: 0960-8923            Impact factor:   4.129


  34 in total

1.  Biliopancreatic Diversion with Gastrectomy as Surgical Treatment of Morbid Obesity.

Authors: 
Journal:  Obes Surg       Date:  1991-12       Impact factor: 4.129

2.  Biliopancreatic diversion for treatment of morbid obesity: experience in 180 consecutive cases.

Authors:  E Totté; L Hendrickx; R van Hee
Journal:  Obes Surg       Date:  1999-04       Impact factor: 4.129

3.  Duodenal switch without gastric resection: results and observations after 6 years.

Authors:  Maria Laura Cossu; Giuseppe Noya; Gian Carlo Tonolo; Stefano Profili; Giovanni B Meloni; Matteo Ruggiu; Patrizia Brizzi; Franca Cossu; Luca Pilo; Pier Luigi Tilocca
Journal:  Obes Surg       Date:  2004 Nov-Dec       Impact factor: 4.129

4.  Effect of duodenal-jejunal exclusion in a non-obese animal model of type 2 diabetes: a new perspective for an old disease.

Authors:  Francesco Rubino; Jacques Marescaux
Journal:  Ann Surg       Date:  2004-01       Impact factor: 12.969

5.  Short-, mid- and long-term results of Larrad biliopancreatic diversion.

Authors:  Alvaro Larrad-Jiménez; Carlos Sánchez-Cabezudo Díaz-Guerra; Pedro de Cuadros Borrajo; Irene Bretón Lesmes; Basilio Moreno Esteban
Journal:  Obes Surg       Date:  2007-02       Impact factor: 4.129

6.  [Comparision between a bilio-pacreatic diversion with or without gastroresection after 2 years of follow-up in the treatment of the pathological obesity].

Authors:  Francesco Mittempergher; Ernesto Di Betta; Riccardo Nascimbeni; Claudio Casella
Journal:  Ann Ital Chir       Date:  2008 Jul-Aug       Impact factor: 0.766

7.  Duodenal switch: long-term results.

Authors:  Picard Marceau; Simon Biron; Frédéric-Simon Hould; Stéfane Lebel; Simon Marceau; Odette Lescelleur; Laurent Biertho; Serge Simard
Journal:  Obes Surg       Date:  2007-11       Impact factor: 4.129

8.  Improvement of metabolic syndrome following intragastric balloon: 1 year follow-up analysis.

Authors:  Nicola Crea; Giacomo Pata; Domenico Della Casa; Luigi Minelli; Giovanni Maifredi; Ernesto Di Betta; Francesco Mittempergher
Journal:  Obes Surg       Date:  2009-06-09       Impact factor: 4.129

Review 9.  Glucagonlike peptide 1: a newly discovered gastrointestinal hormone.

Authors:  J J Holst
Journal:  Gastroenterology       Date:  1994-12       Impact factor: 22.682

10.  The validation of the Moorehead-Ardelt Quality of Life Questionnaire II.

Authors:  Melodie K Moorehead; Elisabeth Ardelt-Gattinger; Hans Lechner; Horacio E Oria
Journal:  Obes Surg       Date:  2003-10       Impact factor: 4.129

View more
  15 in total

1.  Nutrient Status 9 Years After Biliopancreatic Diversion with Duodenal Switch (BPD/DS): an Observational Study.

Authors:  Gladys Witt Strain; Mehyar Hefazi Torghabeh; Michel Gagner; Faith Ebel; Gregory F Dakin; Daniel Connolly; Elizabeth Goldenberg; Alfons Pomp
Journal:  Obes Surg       Date:  2017-07       Impact factor: 4.129

2.  Medium-Term Results of Combined Laparoscopic Sleeve Gastrectomy and Modified Jejuno-Ileal Bypass in Bariatric Surgery.

Authors:  Ahmed Hassn; Andreas Luhmann; Samir Rahmani; Gareth Morris-Stiff
Journal:  Obes Surg       Date:  2016-10       Impact factor: 4.129

3.  Glucagon-Like Peptides 1 and 2 Are Involved in Satiety Modulation After Modified Biliopancreatic Diversion: Results of a Pilot Study.

Authors:  Everton Cazzo; José Carlos Pareja; Elinton Adami Chaim; Cláudio Saddy Rodrigues Coy; Daniéla Oliveira Magro
Journal:  Obes Surg       Date:  2018-02       Impact factor: 4.129

Review 4.  Impact of gastrointestinal surgery on cardiometabolic risk.

Authors:  Fady Moustarah; Audrée Gilbert; Jean-Pierre Després; André Tchernof
Journal:  Curr Atheroscler Rep       Date:  2012-12       Impact factor: 5.113

5.  Predictors for remission of major components of the metabolic syndrome after biliopancreatic diversion with duodenal switch (BPDDS).

Authors:  Villy Våge; Roy M Nilsen; Arnold Berstad; Jan Behme; Nils Sletteskog; Ronny Gåsdal; Camilla Laukeland; Gunnar Mellgren
Journal:  Obes Surg       Date:  2013-01       Impact factor: 4.129

6.  Botulinum toxin for chronic anal fissure after biliopancreatic diversion for morbid obesity.

Authors:  Serafino Vanella; Giuseppe Brisinda; Gaia Marniga; Anna Crocco; Giuseppe Bianco; Giorgio Maria
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

7.  Biliopancreatic Diversion for Severe Obesity: Long-Term Effectiveness and Nutritional Complications.

Authors:  María D Ballesteros-Pomar; Tomás González de Francisco; Ana Urioste-Fondo; Luis González-Herraez; Alicia Calleja-Fernández; Alfonso Vidal-Casariego; Vicente Simó-Fernández; Isidoro Cano-Rodríguez
Journal:  Obes Surg       Date:  2016-01       Impact factor: 4.129

8.  The Impact of Biliopancreatic Diversion with Duodenal Switch (BPD/DS) Over 9 Years.

Authors:  Gladys W Strain; Mehyar H Torghabeh; Michel Gagner; Faith Ebel; Gregory F Dakin; Jonathan S Abelson; Daniel Connolly; Alfons Pomp
Journal:  Obes Surg       Date:  2017-03       Impact factor: 4.129

9.  Preoperative prediction of growth hormone (GH)/insulin-like growth factor-1 (IGF-1) axis modification and postoperative changes in candidates for bariatric surgery.

Authors:  Francesco Mittempergher; Giacomo Pata; Nicola Crea; Ernesto Di Betta; Antonio Vilardi; Deborah Chiesa; Riccardo Nascimbeni
Journal:  Obes Surg       Date:  2013-05       Impact factor: 4.129

Review 10.  Bariatric surgery: the challenges with candidate selection, individualizing treatment and clinical outcomes.

Authors:  K J Neff; T Olbers; C W le Roux
Journal:  BMC Med       Date:  2013-01-10       Impact factor: 8.775

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.